International Journal of Cancer Management

Published by: Kowsar

The Effect of Duloxetine on Tau Protein and Migration in Breast Cancer Cell Line

Bahareh Zarrin 1 , 2 , Shaghayegh Haghjooy Javanmard 1 , 2 , Fariba Samani 1 , Mohamadhasan Tajadini 1 , Maryam Jamady 1 , Neda Esmaeli 1 , Ahmed Ghasemi 1 , 2 and Golnaz Vaseghi 3 , *
Authors Information
1 Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IR Iran
2 Department of Physiology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, IR Iran
3 Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IR Iran
Article information
  • International Journal of Cancer Management: May 2017, 10 (5); e6422
  • Published Online: May 16, 2017
  • Article Type: Research Article
  • Received: April 17, 2016
  • Revised: August 12, 2016
  • Accepted: April 29, 2017
  • DOI: 10.5812/ijcm.6422

To Cite: Zarrin B, Haghjooy Javanmard S, Samani F, Tajadini M, Jamady M, et al. The Effect of Duloxetine on Tau Protein and Migration in Breast Cancer Cell Line, Int J Cancer Manag. 2017 ; 10(5):e6422. doi: 10.5812/ijcm.6422.

Abstract
Copyright © 2017, International Journal of Cancer Management. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Khanfir A, Lahiani F, Bouzguenda R, Ayedi I, Daoud J, Frikha M. Prognostic factors and survival in metastatic breast cancer: A single institution experience. Rep Pract Oncol Radiother. 2013; 18(3): 127-32[DOI][PubMed]
  • 2. Megerdichian C, Olimpiadi Y, Hurvitz SA. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer. Cancer Treat Rev. 2014; 40(5): 614-25[DOI][PubMed]
  • 3. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. 2000; 33(1): 95-130[PubMed]
  • 4. Goedert M. Tau protein and neurodegeneration. Semin Cell Dev Biol. 2004; 15(1): 45-9[DOI][PubMed]
  • 5. Wang JZ, Liu F. Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol. 2008; 85(2): 148-75[DOI]
  • 6. Honore S, Pasquier E, Braguer D. Understanding microtubule dynamics for improved cancer therapy. Cell Mol Life Sci. 2005; 62(24): 3039-56[DOI][PubMed]
  • 7. Smoter M, Bodnar L, Duchnowska R, Stec R, Grala B, Szczylik C. The role of Tau protein in resistance to paclitaxel. Cancer Chemother Pharmacol. 2011; 68(3): 553-7[DOI][PubMed]
  • 8. Yared JA, Tkaczuk KH. Update on taxane development: new analogs and new formulations. Drug Des Devel Ther. 2012; 6: 371-84[DOI][PubMed]
  • 9. McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008; 1785(2): 96-132[DOI][PubMed]
  • 10. Ren QG, Wang YJ, Gong WG, Zhou QD, Xu L, Zhang ZJ. Escitalopram Ameliorates Forskolin-Induced Tau Hyperphosphorylation in HEK239/tau441 Cells. J Mol Neurosci. 2015; 56(2): 500-8[DOI][PubMed]
  • 11. Nelson RL, Guo Z, Halagappa VM, Pearson M, Gray AJ, Matsuoka Y, et al. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp Neurol. 2007; 205(1): 166-76[DOI][PubMed]
  • 12. Gil-Ad I, Zolokov A, Lomnitski L, Taler M, Bar M, Luria D, et al. Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice. Int J Oncol. 2008; 33(2): 277-86[PubMed]
  • 13. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007; (4)[DOI][PubMed]
  • 14. Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, Woelfle U, Rau T, Sauter G, et al. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res. 2005; 11(22): 8006-14[DOI][PubMed]
  • 15. Bhat KM, Setaluri V. Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res. 2007; 13(10): 2849-54[DOI][PubMed]
  • 16. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A. 2005; 102(23): 8315-20[DOI][PubMed]
  • 17. Biglia N, Bounous VE, Susini T, Pecchio S, Sgro LG, Tuninetti V, et al. Duloxetine and escitalopram for hot flushes: efficacy and compliance in breast cancer survivors. Eur J Cancer Care (Engl). 2016; [DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments